Autonomix medical, inc. announces pricing of $9.0 million underwritten public offering

The woodlands, tx, nov. 22, 2024 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $9.0 million prior to deducting underwriting discounts and commissions and offering expenses.
AMIX Ratings Summary
AMIX Quant Ranking